Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00179465 · ClinicalTrials.gov registry record · Phase 3
Treating Schizophrenia by Correcting Abnormal Brain Development
A Phase 3 study of Schizophrenia, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 3
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00179465 is a Phase 3 study of Schizophrenia that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 36 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00179465, a Phase 3 study of Schizophrenia, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tiagabine
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-11 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00179465
The ClinicalTrials.gov registry entry for NCT00179465 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (84% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00179465 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00179465 about?
NCT00179465 is a clinical study titled "Treating Schizophrenia by Correcting Abnormal Brain Development". The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
What is the current status of trial NCT00179465?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 36 participants. The study started on 2003-11. Estimated completion is 2026-09.
What conditions does trial NCT00179465 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00179465?
The interventions under investigation include: Placebo (DRUG), Tiagabine (DRUG).
Who is sponsoring clinical trial NCT00179465?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00179465 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.